Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Previously presented) A method of magnetic resonance imaging of a sample, said method comprising:
- i) administering a hyperpolarised MR imaging agent in liquid phase comprising non-zero nuclear spin nuclei into the sample;
- ii) exposing the sample to a radiation at a frequency selected to excite nuclear spin transitions in said non-zero nuclear spin nuclei;
- iii) detecting MR signals from the sample and utilising spectral-spatial excitation, in combination with a FISP or PSIF pulse sequence with a flip angle of 45 to 90 degrees; and
- iv) optionally generating an image, physiological data or metabolic data from said detected signals.
- 2. Canceled.
- 3. Canceled.
- 4. Canceled.
- 5. (Previously presented) The method as claimed in claim 1 wherein said non-zero nuclear spin nuclei are selected from the group consisting of ¹H, ³He, ³Li, ¹³C, ¹⁵N, ¹⁹F, ²⁹Si, ³¹P and ¹²⁹Xe.
- 6. (Previously presented) The method as claimed in claim 1 wherein said non-zero nuclear spin nuclei are selected from the group consisting of ¹³C and ¹⁵N.
- 7. (Previously presented) The method as claimed in claim 1 wherein said MR imaging agent is artificially enriched above natural abundance in the MR imaging nucleus.
- 8. (Original) The method as claimed in claim 6 wherein the MR imaging agent has an effective nuclei ¹³C polarisation of more than 1%.

- 9. (Original) The method as claimed in claim 6 wherein the MR imaging agent is ¹³C enriched at carbonyl or quaternary carbon positions.
- 10. (Original) The method as claimed in claim 9 wherein said ¹³C enriched compound is deuterium labelled adjacent said ¹³C nucleus.
- 11. (Previously presented) The method as claimed in claim 6 wherein said ¹³C nuclei are surrounded by one or more non-MR active nuclei or entities selected from the group consisting of O, S, C, a double bond, and a triple bond.
- 12. Canceled.
- 13. (Previously presented) The method as claimed in claim 1 wherein said imaging agent comprises a compound selected from pyruvate,

- 14. (Previously presented) The method as claimed in claim 1 wherein said non-zero nuclear spin nuclei are ¹³C nuclei.
- 15. (Previously presented) The method as claimed in claim 1 wherein the sample is a human or non-human animal body.
- 16. (Currently amended) The method of claim 15 wherein step iii) is carried out after the agent has left the <u>a</u> vascular bed and wherein step iv) metabolic data are generated from said detected signals.